Reporting from EULAR 2024 – Frederic Lavie, MD, PhD: Guselkumab Provides Robust Improvements in Pain Among Patients with PsA

Reporting from EULAR 2024 – Frederic Lavie, MD, PhD: Guselkumab Provides Robust Improvements in Pain Among Patients with PsA The inspiration for the Cosmos phase 3b study came from discussions that investigators, including Frederic Lavie, MD, PhD, head of Global Medical Affairs Rheumatology at the Janssen Pharmaceutical Companies of Johnson & Johnson, had with providers […]

Newly reported from EULAR 2024: CT-P47 Is Promising Biosimilar Candidate for Tocilizumab in RA Treatment

Newly reported from EULAR 2024: CT-P47 Is Promising Biosimilar Candidate for Tocilizumab in RA Treatment Phase 3 data presented at the Annual European Congress of Rheumatology (EULAR) 2024 found the biosimilar CT-P47 is similar in terms of efficacy, safety, and immunogenicity profile to the reference product, tocilizumab (RoActemra), for treating patients with moderate-to-severe rheumatoid arthritis (RA). “The […]

Newscasting from EULAR 2024 – Frederic Lavie, MD, PhD: Guselkumab Demonstrates Rapid, Sustained Improvements in Severe PsA

Newscasting from EULAR 2024 – Frederic Lavie, MD, PhD: Guselkumab Demonstrates Rapid, Sustained Improvements in Severe PsA Treatment with guselkumab led to rapid, clinically meaningful improvements in disease activity among patients with severe psoriatic arthritis (PsA), which were maintained through 2 years. In an interview with HCPLive, Frederic Lavie, MD, PhD, head of Global Medical Affairs Rheumatology […]

Broadcasting from EULAR 2024 – Frederic Lavie, MD, PhD: cDAPSA Demonstrates Efficacy in Monitoring Disease Activity in PsA

Broadcasting from EULAR 2024 – Frederic Lavie, MD, PhD: cDAPSA Demonstrates Efficacy in Monitoring Disease Activity in PsA Post hoc analyses of the DISCOVER-1 and DISCOVER-2 trials demonstrated the promising effects of guselkumab, a fully human interleukin (IL)-23p19-subunit inhibitor, on the Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA) among a cohort of patients with […]

Newscasting from EULAR 2024: Phase 3 Upadacitinib Trial Shows Promising Results for Giant Cell Arteritis Treatment

Newscasting from EULAR 2024: Phase 3 Upadacitinib Trial Shows Promising Results for Giant Cell Arteritis Treatment In an interview with HCPLive, Daniel Blockmans, MD, PhD, discussed a phase 3, randomized, placebo-controlled trial that compared 2 doses of upadacitinib versus placebo among a cohort of patients with giant cell arteritis (GCA). The findings, presented at the 2024 European […]

Broadcasting from EULAR 2024: TNX-102 SL Significantly Reduces Daily Pain, Improves Fibromyalgia Symptoms

Broadcasting from EULAR 2024: TNX-102 SL Significantly Reduces Daily Pain, Improves Fibromyalgia Symptoms Phase 3 data showed TNX-102 SL (sublingual cyclobenzaprine HCI; Tonmya) significantly reduced daily pain and improved broad fibromyalgia symptoms. Tonix Pharmaceuticals presented a poster of their pivotal trial, RESILIENT, at the Annual European Congress of Rheumatology (EULAR) 2024 in Vienna, Austria. The study evaluated TNX-102 SL […]

News Coverage from EULAR 2024: Benefits of Early Belimumab Intervention in SLE, with Karen Costenbader, MD

News Coverage from EULAR 2024: Benefits of Early Belimumab Intervention in SLE, with Karen Costenbader, MD In an interview with HCPLive,Karen Costenbader, MD, director of the Lupus Program at Brigham and Women’s Hospital, gives an overview of 2 analyses that demonstrated treatment with belimumab reduces flares and increases Systemic Lupus Erythematosus Responder Index 4 (SRI-4) response […]

ESC Congress Recap: High-Impact Clinical Trials, with Deepak Bhatt, MD, MPH, MBA

ESC Congress Recap: High-Impact Clinical Trials, with Deepak Bhatt, MD, MPH, MBA With 32,000 attendees from more than 170 countries, the European Society of Cardiology (ESC) Congress 2024 demonstrated how it has earned the reputation as 1 of the foremost scientific meetings in cardiology and medicine as a whole. Boasting 4,400 novel abstracts, including 112 studies simultaneously […]